Icon

Inrebic - (100 mg; Capsule)

Fedratinib Hydrochloride Impact
100 mg; Capsule
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
INREBIC is a kinase inhibitor indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Yes
*** *********** **** ****** ** *** **, ****. ****** ************, ***., ** * ******-***** ********** ** ******* ***********. ***** *** **** **** ** **- *****://***.***.***/**?***=/********/*****/****/*****/******************/***-********.***
Inrebic Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
**** ******* **** *** ******* **** *** ******* **** *** ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
**** *** \ ********* *** **, **** ******* ********* ******** ******* *** **** *** **** ****
  1. *** **, **** : **** ** ** ***** *** ***** ** *** ***.
  2. *** **, **** : **** ******** ****** ** ***** **** ** ****** **** ******* ** '***, *** '***.
  3. *** **, **** : ****** **** **** **** ************ ** ****** ** '***, *** '***.
  4. *** **, **** : ********* ** **'* ******* *********, ****** *** **** ******* ********** **** ************ ** ******* '*** *** '***. ****** ****** **** ** **** ********** **** **** **********.
  5. : ** *** *** - ****** ****** **** *** ****** '*** *** *** *** **** *** **, ****. (*****://***.***.***/**?***=/********/*****/****/*****/******************/***-********.***)

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.